China pharmacist Tu Youyou's award will affect the following stocks:

1, Kunming Pharmaceutical

2, Fosun Pharmaceutical

3, Baiyunshan Pharmaceutical

Tu Youyou's reason for winning the award is: "The discovery of artemisinin, a drug used to treat malaria, has saved millions of lives around the world, especially in developing countries."

At present, there are two kinds of artemisinin preparations produced in China: artemether, the exclusive product developed by Kunming Pharmaceutical, and artesunate, which is produced by Guilin Nanyao, a subsidiary of Fosun Pharma, both of which are based on artemisinin. With the gradual recovery of artemisinin bulk drug market, several large domestic enterprises engaged in artemisinin production in the early days, such as Shanghai Fosun, Guangzhou Pharmaceutical Group and Hubei Enhua Bio, have started a new round of production expansion. It is reported that GPHL plans to expand the production scale of artemisinin API to 8 tons per year, and Hubei Enhua Bio and Shanghai Fosun also have their own expansion plans. However, at present, only two enterprises in China, Kunming Pharmaceutical Factory and Guilin Nanyao, have obtained the supplier qualification of UN artemisinin preparations, and other enterprises can only "borrow ships to go to sea", that is, export their products through the orders of qualified foreign pharmaceutical companies.

Artemisinin raw material medicine, which was neglected in the previous two years, has become hot again since last year: many international charitable funds, such as Clinton Foundation and Global Fund, have joined the purchasing army of artemisinin preparations. By the end of 29, the price of artemisinin raw material medicine in Chongqing market, the largest planting place of Artemisia annua and the production base of artemisinin raw material medicine in China, has recovered to the level of 25, with a price of 2,5 yuan per kilogram, and the purchase price of fresh grass has also rapidly increased to 6 yuan per kilogram. At the same time, there is also an upsurge of artemisinin development in the international pharmaceutical field.